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Retroperitoneal Fibrosis in 27 Korean Patients: Single Center 
Experience
Retroperitoneal fibrosis (RPF) is a rare disease with unclear etiology, which is characterized 
by chronic non-specific inflammation of the retroperitoneum. This study was performed to 
investigate the clinical characteristics, laboratory findings, radiologic findings, treatment 
and outcome in Korean patients with RPF. We retrospectively reviewed medical records of 
27 RPF patients who were admitted to Yonsei University Medical Center between 1998 and 
2009. Twenty-two patients (81%) were male. The mean age at diagnosis was 56 yr. Nine 
patients had identifiable risk factors of RPF and three patients had combined autoimmune 
diseases. Acute phase reactants were elevated in most patients. Rheumatoid factor was 
positive in 3 of 16 patients (19%) and antinuclear antibody in 4 of 17 (24%). Five of 6 
patients who were taken positron-emission tomography showed positive uptake. 
Glucocorticoids were used in 16 patients (59%) and four of them received combination 
therapy with azathioprine. After immunosuppressive treatment, the levels of acute phase 
reactants dropped, and the size of mass also decreased in most patients. In conclusion, the 
clinical characteristics of RPF in Korean patients are similar with other series except for 
higher proportion of male. Some patients with RPF have autoimmune features. The effect 
of immunosuppressive treatment on RPF is good.
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INTRODUCTION
Retroperitoneal fibrosis (RPF) is a rare disorder with unclear 
etiology, first described by Ormond in 1948 (1). It is character-
ized by the presence of retroperitoneal tissue consisting of chron-
ic inflammation and marked fibrosis which usually develops 
around the infrarenal portion of the abdominal aorta and the 
iliac arteries (2). The hallmark of the disease and its main com-
plication is ureteral entrapment which is often silent and pro-
gressive. RPF is divided into primary idiopathic and secondary 
disease, and the latter have clearly identifiable causes such as 
radiation therapy, drugs, infection, surgery, and cancer (3). How-
ever, this distinction is vague, since direct causal relationship be-
tween secondary cause and RPF is unclear and some authors 
consider these conditions (particularly surgery, radiation, and 
drugs) as only predisposing factors. 
 The pathogenesis of RPF is unclear, but numerous theories 
have been discussed in previous reports. Possibilities include 
genetic component (4), environmental factor (5), immunologic 
process such as IgG4-bearing plasma cell deposition (6), and 
local inflammatory complication of advanced atherosclerosis 
(7). Several studies have noted an increased incidence of com-
bined autoimmune disease and/or autoantibody positivity in 
idiopathic RPF and in chronic periaortitis (8). However, some 
series revealed that associated autoimmune diseases and/or au-
toantibodies in RPF were not frequent (9). 
 So far, most reports have focused on RPF patients from west-
ern countries, and series on Asian populations are rare (10, 11). 
Furthermore, clinical data in Korean patients is limited to case 
reports or small series. In this study, we investigated the clinical 
characteristics, laboratory findings, radiologic findings, treat-
ment and outcomes of Korean patients with RPF. 
MATERIALS AND METHODS
Patients
We reviewed medical records of RPF patients who had been di-
agnosed at Yonsei University Medical Center, Seoul, Korea be-
tween January 1998 and December 2009. These patients include 
one case previously published as a case report (12).
 Diagnosis of RPF was based on the typical clinical feature and 
the presence of characteristic findings on computed tomogra-
phy (CT) or magnetic resonance imaging (MRI). A typical im-
aging finding of RPF is a well-defined retroperitoneal soft-tissue 
attenuation mass, enveloping but not displacing the lower ab-
dominal aorta with caudal extension following the bifurcation 
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of the iliac vessels. Retroperitoneal biopsies were performed in 
some patients if the imaging findings were atypical or differen-
tiation of malignancy was needed. Patients with concurrent ma-
lignancy were excluded. 
Data collection
For each patient, the following data were recorded: demograph-
ic information, clinical features, laboratory and immunologic 
parameters at the time of diagnosis, treatment, outcome, and 
duration of follow-up. Demographic information included age, 
sex, smoking, associated comorbidities such as hypertension, 
diabetes, dyslipidemia, coronary artery disease, cerebrovascu-
lar disease, and the presence of autoimmune diseases. Clinical 
features included the duration of symptoms, signs and symp-
toms. Clinical symptoms were divided into two types: localized 
and systemic according to a previous study (13). Localized symp-
toms included pain, edema of lower limbs, scrotal swelling, and 
claudication probably caused by mechanical or compressive 
effects of RPF. Systemic symptoms included fatigue, weight loss, 
anorexia, and fever, reflecting systemic inflammatory responses. 
Laboratory parameters included white blood cell (WBC) and 
platelet counts, hemoglobin, erythrocyte sedimentation rate 
(ESR), C-reactive protein (CRP), blood urea nitrogen (BUN), cre-
atinine, and albumin. Immunologic parameters included the 
presence of rheumatoid factor (RF), antinuclear antibody (ANA), 
other autoantibodies, or IgG4 level. 
 
Imaging data
Results of the imaging studies (CT scan or MRI) were reviewed. 
Mass localization was recorded for each patient. We noted the 
presence or absence of hydronephrosis, atrophic kidneys, and 
localized lymphadenopathy. The maximal thickness (mm) of 
RPF mass was measured in the transverse view of CT or MRI 
scan. Image findings were classified according to a previously 
described classification system (14). 
 Class I, soft-tissue density surrounding the infrarenal aorta 
           and/or iliac vessels;
 Class II, soft-tissue density surrounding the infrarenal vena 
           cava;
 Class III, lateral extension of the inflammation/fibrosis with 
           compression of one or both ureters;
 Class IV, extension of fibrosis which includes the renal hilum 
           with compression of the renal artery and/or renal vein.
 Findings of dynamic nuclear imaging with 67gallium single 
photon emission CT (67Ga SPECT) and/or 18F-fluorodeoxyglu-
cose positron emission tomography (18F-FDG-PET) were col-
lected. 
Statistical analysis
Continuous variables were described as mean ± standard devi-
ation (SD), and as median and interquartile range (IQR, 25th-
75th percentile) in case of skewed distribution. Qualitative vari-
ables were expressed as a percentage. A P value of < 0.05 was 
considered significant. All statistical analyses were performed 
with SPSS software (version 13.0; SPSS Inc., Chicago, IL, USA).
Ethics statement
The study protocol was approved by the institutional review 
board of the Yonsei University College of Medicine (IRB No. 
4-2010-0428). Informed consent was waived by the IRB.
RESULTS
Patient characteristics
Data were obtained from 27 patients. Patient characteristics are 
described in Table 1. Most patients (n = 21, 78%) were between 
the ages of 40 and 70 yr, and the mean age was 56 yr old. Twenty 
two patients were male, giving a male to female ratio of 4.4:1. 
The symptom duration varied from 1 day to 2 yr with the medi-
an of 2 months. Age and symptom duration did not differ be-
tween men and women. 
 Cardiovascular risk factors were present in many patients. 
Ten patients (37%) had hypertension, and 2 (7%) had dyslipid-
emia. Coronary heart disease was diagnosed in 3 patients (11%) 
and cerebrovascular disease in 2 patients (7%). Smoking status 
was as follows: 7 current smokers, 7 former smokers, and 13 pa-
tients who never smoked. Three patients had previous or con-
Table 1. Demographic and clinical characteristics of the patients
Characteristics Number (%)
Number of patients 27
Age (yr) (mean ± SD)   55.7 ± 13.3
Sex (M : F) 22: 5
Duration of symptoms, month (median [25-75 percentile]) 2 (0.5-4)
Comorbid conditions
   Coronary artery disease
   Cerebral vascular disease
   Hypertension
   Dyslipidemia
 
  3 (11)
2 (7)
10 (37)
2 (7)
Smoking
  Current smoker
  Ever smoker
  7 (26)
  7 (26)
Autoimmune disease
  Hashimoto thyroiditis
  Autoimmune pancreatitis
2 (7)
1 (4)
Body mass index (kg/m2) (mean ± SD) 23.2 ± 2.9
Systolic blood pressure (mmHg) (mean ± SD) 135 ± 19
Diastolic blood pressure (mmHg) (mean ± SD)   83 ± 12
SD, standard deviation.
Table 2. Patients with predisposing factors for developing retroperitoneal fibrosis
Risk factors Number (%)
Prior use of β-blockers 2 (7)
History of tuberculosis 1 (4)
Prior abdominal or pelvic surgery 5 (19)
Occupation with risk of asbestos exposure 1 (4)
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current autoimmune diseases: Hashimoto thyroiditis in 2 pa-
tients and autoimmune pancreatitis in one.
 Nine patients had identifiable predisposing factors for devel-
oping RPF (Table 2). Five patients had a history of abdominal 
surgery. Two patients had a history of β-blocker use. One patient 
whose occupation was a mine worker had a history of occupa-
tional exposure to asbestos. High resolution chest CT scan of 
the patient revealed multiple centrilobular, interlobular septal 
or fissural nodules predominantly in both upper and posterior 
lungs and enlargement of multiple lymph nodes at both hilum 
and mediastinum, consistent with pneumoconiosis.
Clinical manifestations
Table 3 shows patients’ clinical manifestations at presentation. 
Localized symptoms were present in 24 patients (89%), and sys-
temic symptoms in 15 (56%). Pain was the most common symp-
tom, with 18 patients (67%) complaining of abdominal, back or 
flank pain. Fever, weight loss, generalized weakness, and oligu-
ria were common symptoms. Other symptoms were nausea, 
vomiting, lower extremity edema, anorexia, and hematuria. In 
one asymptomatic patient, RPF was diagnosed due to inciden-
tal hydronephrosis detected by abdominal ultrasonography at 
routine health checkup. 
Laboratory findings
Laboratory findings showed normocytic anemia (48%), leuko-
cytosis (26%), and hypoalbuminemia (22%) (Table 4). The mean 
hemoglobin level was 12.5 g/dL (range: 8.8-17.4 g/dL). Eleva-
tion in the ESR and CRP was observed in most of patients (90%, 
78%, respectively).
 Eight patients (30%) presented with impaired renal function, 
and all of them had hydronephrosis. Rheumatoid factor was pos-
itive in 3/16 patients (19%) and antinuclear antibody was posi-
tive in 4/17 patients (24%). One patient had anti-Ro antibody, 
one patient lupus anticoagulant, and one patient anti-DNA anti-
body. High titer of serum IgG4 was observed in 2 patients (about 
three times higher than upper normal value). 
Radiologic findings
Table 5 shows the result of the radiographic classification of pa-
tients with RPF. The most common type was class I + III. Eigh-
teen patients had hydronephrosis requiring ureteral stenting. 
Six patients were bilateral, seven were unilateral left-sided, and 
five were unilateral right-sided obstructions. Localized lymph-
adenopathy adjacent to the RPF mass was noted in 9 patients. 
Renal atrophy was found in 4 patients. Renal vessel involvement 
was noted in 2 patients. 
 Dynamic nuclear imaging was carried out in seven patients 
(67Ga SPECT in 1 patient, 18F-FDG-PET in 6 patients). Nuclear 
imaging showed pathologic 67Ga or 18F-FDG uptake at the level 
of the retroperitoneal mass in 6 patients (86%). 
Histologic findings
In 16 patients final diagnosis was established by histologic ex-
amination. In all cases, the ureters were surrounded by dense 
fibrotic tissue with chronic inflammation. One patient’s biopsy 
tissue was examined with immunohistochemical staining of 
IgG4, and the result showed dense IgG4-positve plasma cell in-
filtration (IgG4-positive plasma cells: 100/high power field).
Table 3. Clinical manifestations at presentation in 27 patients with RPF
Characteristics Number (%)
Localized symptoms* 24 (89)
Systemic symptoms† 15 (56)
Pain
   Flank
   Abdominal
   Back
18 (67)
10
  7
  1
Fever   7 (26)
Weight loss   7 (26)
Generalized weakness   7 (26)
Oliguria   7 (26)
Nausea, vomiting   6 (22)
Lower extremity edema   6 (22)
Anorexia   5 (19)
Hematuria   4 (15)
Constipation   3 (11)
Urinary frequency 2 (7)
Thromboembolism 1 (4)
Anejaculation 1 (4)
*pain, edema of lower limbs, scrotal swelling, claudication; †fatigue, weight loss, an-
orexia, fever.
Table 4. Laboratory findings at presentation
Characteristics    Number (%)
WBC (× 103/mL) (mean ± SD)   8.84 ± 4.04
Leukocytosis*   7 (26)
Hb (g/dL) (mean ± SD) 12.5 ± 2.2
MCV (fL) (mean ± SD)   95.2 ± 39.2
Anemia† 13 (48)
Platelet (× 103/mL) (mean ± SD)   297 ± 129
Albumin (g/L) (mean ± SD)   4.0 ± 0.6
Hypoalbuminemia‡   6 (22)
ESR (mm/hr) (mean ± SD)   70 ± 35
CRP (mg/dL) (mean ± SD)   3.2 ± 2.8
Increased acute phase reactants
  ESR
  CRP
  
19/20 (90)
14/18 (78)
Creatinine level (mg/dL)
   Overall (mean ± SD)
   Patients with hydronephrosis (mean ± SD)
 
  1.97 ± 2.10
  2.52 ± 2.41
Impaired renal function§   8 (30)
Positive autoantibody
   Rheumatoid factor
   Antinuclear antibody
  7/17 (41)
  3/16 (19)
  4/17 (24)
*WBC > 10.8 × 103/mL; †Hb < 12 g/dL in women and 13 g/dL in men; ‡albumin < 3.3 
g/L; §creatinine > 1.4 mg/dL. WBC, white blood cell; SD, standard deviation; Hb, he-
moglobin; MCV, mean corpuscular volume; ESR, erythrocyte sedimentation rate; CRP, 
C-reactive protein.
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Treatment and outcome
The mean duration of follow-up was 36 (range 2-144) months. 
Treatment consisted of immunosuppression only (n = 7), surgi-
cal intervention (open or laparoscopic biopsy with ureterolysis) 
without immunosuppression (n = 8), and a combination of both 
(n = 9). Ureteral obstruction was treated by intraureteral stent in-
sertion with a double J catheter. Immunosuppressive agents were 
used in 16 patients and the initial regimen consisted of moder-
ate to high-dose glucocorticoids. The average initiation dose of 
prednisolone was 50 mg daily (20-60 mg prednisolone/day) and 
it was tapered to a low dosage of < 10 mg/day within 3-6 months. 
Four patients received combination therapy with azathioprine. 
The mean dosage of azathioprine was 100 mg daily. All of them 
responded, but one patient discontinued azathioprine due to 
drug-induced hepatitis. After treatment of glucocorticoid and/
or azathioprine, ESR or CRP decreased to normal level, and the 
size of mass on CT imaging was decreased in most patients (mean 
maximal thickness of the RPF: 13.4 → 6.4 mm). There were 2 cases 
of recurrence. The lesion recurred after only surgical treatment 
in 1 patient and other patient experienced the recurrence 14 
months after tapering off glucocorticoid. One patient died of 
amyloidosis 8 yr after the diagnosis of RPF. 
DISCUSSION
In this study, we investigated demographic, clinical, and radio-
logic features of 27 Korean patients with RPF who were diagnosed 
at a single referral center. The incidence of RPF is unknown, and 
the estimates vary from 1:200,000-1:500,000 per year (15). Al-
though a small number of patients were enrolled in this study, 
the number might not be small considering the rarity of the dis-
ease.
 RPF occurred between the age of 40 and 70 yr in most of our 
patients. This result is consistent with studies reported in the U.S. 
and European countries (14, 16). Men were more likely to devel-
op RPF than women. In our study, the male to female ratio was 
4.4. This result is somewhat higher than that of previous studies 
in which the ratio ranged from 1.8 to 3.3 (16-18). It is thought that 
male predominance is associated with increased atherosclerot-
ic disease related to pathogenesis of RPF (17). 
 Recent studies suggested that RPF usually develops in patients 
with cardiovascular risk factors (2, 15, 19). Several factors such 
as medication (β-blocker, hydralazine or methylsergide), sur-
gery, radiation, infections, and exposure to asbestos have been 
described as predisposing factors for developing RPF, despite a 
scarcity of data to establish a clear causal relationship (2, 5, 20). 
In our study, many patients had cardiovascular risk factor such 
as hypertension, dyslipidemia, and tobacco exposure, and 18% 
of patients already had a cerebrovascular disease. Our patients 
had several predisposing factors for RPF such as previous ab-
dominal surgery, β-blocker use, tuberculosis, and exposure to 
asbestos. 
 The most common symptom in our patients was pain (abdom-
inal, flank or back) which was similar to other reports (14, 16, 17). 
Other frequent symptoms were fever, weight loss, generalized 
weakness, and oliguria. Lower extremity edema was also com-
mon symptoms, reflecting the compression of the ilio-femoral 
veins by RPF. Systemic constitutional symptoms are common, 
similar to published series (13, 17), although more patients in 
our study had fever.
 Laboratory data showed signs of an inflammatory disease. 
Increased levels of acute-phase reactants such as ESR and CRP 
were observed in most patients. Although azotemia was present 
in 50% to 70% of patients in several earlier studies (16), it was less 
common in recent series (30%) (15). Elevated levels of serum 
creatinine were observed in 30% of our patients, consistent with 
recent studies (21). These abnormal laboratory findings were 
improved after immunosuppressive treatment in most patients. 
 Several studies have proposed that RPF is a systemic autoim-
mune disease that is frequently associated with other autoim-
mune diseases or autoantibody positivity (4, 8, 22), whereas oth-
er studies suggested that RPF is less likely to be associated with 
autoimmune disease or autoantibody (9, 23). In our study, ANA 
was positive in 24% of patients and RF in 19%. Five patients were 
Table 5. Radiologic findings at diagnosis in patients with RPF
Characteristics Number (%)
Location of mass
   Periaortic, periiliac
   Periaortic
   Periaortic, pericaval
   Presacral
   Retrovesical
   Paracolic
 
  7 (26)
11 (41)
11 (41)
2 (7)
1 (4)
  4 (15)
Classification system*
   I
   I + II
   I + III
   I + IV
   I, II, III
   II + IV
   I, II, III, IV
 
  5 (19)
1 (4)
10 (37)
2 (7)
  6 (22)
1 (4)
2 (7)
Hydro-ureteronephrosis
   Bilateral
   Unilateral
18 (67)
  6 (33)
12 (67)
Localized lymphadenopathy   9 (33)
Renal atrophy   4 (15)
Renal vessel involvement 2 (7)
Nuclear imaging 7
67Ga SPECT 1
18FDG-PET 6
Positive uptake 6
*Classification system. Class I, soft-tissue density surrounding the infrarenal aorta 
and/or iliac vessels; Class II, soft-tissue density surrounding the infrarenal vena cava; 
Class III, lateral extension of the inflammation/fibrosis with compression of one or 
both ureters; Class IV, extension of fibrosis which includes the renal hilum with com-
pression of the renal artery and/or renal vein. SPECT, single photon emission tomog-
raphy; FDG-PET, fluorodeoxyglucose -positron emission tomography.
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associated with autoimmune disease or specific autoantibody 
(two Hashimoto thyroiditis, one autoimmune pancreatitis, one 
anti-DNA and anti-RNP positivity, one anti-Ro positivity). The 
pati ents with anti-DNA, anti-RNP, or anti-Ro positivity were not 
diagnosed with specific connective tissue disease like systemic 
lupus erythematosus, mixed connective tissue disease, or Sjo-
gren syndrome due to lack of specific manifestations. Since it is 
noted that autoimmune diseases become overt late in the course 
of RPF (24), careful follow-up regarding the development of spe-
cific autoimmune diseases should be needed in these patients. 
Based on these findings, RPF might be a sign of a systemic au-
toimmune disease in selected cases. Therefore, it is important 
to investigate the coexistence of other autoimmune condition 
in patients diagnosed with RPF. 
 A method of Scheel and Feeley (14) was applied to classify ra-
diologic findings of RPF. In their series, class I + II + III, I + II + III+ 
IV, I, and I + II was common. They suggest the possibility that dif-
ferent classes have different clinical outcomes or complications. 
For example, class II (periaortic plus pericaval involvement) could 
be associated with increased risk of thromboembolic events. In 
our study, the most common type was class I + III.
 Five of 6 patients who were taken PET in our study showed 
positive uptake. 18F-FDG-PET is an established functional im-
aging modality in detecting neoplastic and inflammatory dis-
eases (25, 26). Although the pathogenesis of RPF is unclear, one 
leading hypothesis is that RPF arises as a result of local reaction 
to antigens found in the atherosclerotic plaque, leading to aor-
tic-periaortic inflammation and disproportionate fibrogenic re-
action (2, 22). Furthermore, RPF is occasionally accompanied by 
malignant diseases (2). Vaglio et al. (27) suggested that 18F-FDG-
PET might be a useful functional imaging modality in assessing 
disease activity. However, another study reported that PET was 
not adequate to evaluate the treatment responses (28). We sug-
gest 18F-FDG-PET to be useful tool to detect active RPF as well 
as to rule out malignant diseases. Further research is needed to 
investigate the role of PET in RPF patients.
 The treatment strategy of RPF includes the removal of any 
identifiable inciting agent, preservation of renal function and 
suppression of the inflammatory process. Although some reports 
showed favorable results with surgical treatment only, the rate of 
recurrence was high in patients who were treated with surgery 
only (15). In recent years, glucocorticoid with or without ureter-
al decompression is considered as standard treatment. Although 
it is difficult to compare effects of each treatment modality, glu-
cocorticoid with ureteral stent insertion is thought as an appro-
priate treatment for patients with hydronephrosis (29). 
 Recently, Kamisawa and Okamoto (30) suggested a new dis-
ease entity called “IgG4-related sclerosing disease” which in-
cludes autoimmune pancreatitis, sclerosing cholangitis, scleros-
ing sialadenitis, and retroperitoneal fibrosis. This disease entity 
is characterized by extensive IgG4-positive plasma cell and T-
lymphocyte infiltration of various organs. In our patients, mea-
surement of serum IgG4 was performed just in two patients, and 
immunohistochemical staining of IgG4 in tissue biopsy of one 
patient. The former two patients showed high levels of serum 
IgG4, and the latter one patient showed the infiltration of IgG4 
positive cells in retroperitoneal tissue. To confirm the associa-
tion between IgG4-related sclerosing disease and RPF, further 
research is needed.
 In conclusion, RPF in Korean patients shows similar clinical 
features found in other series, with the exception of higher pro-
portion of male. Some patients with RPF have autoimmune fea-
tures, and the immunosuppressive treatment is effective. 
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We investigated the clinical characteristics and outcome in 27 Korean patients with retroperitoneal fibrosis (RPF). Nine patients 
had identifiable risk factors of RPF. Parameters indicating autoimmune tendency were often identified, acute phase reactants were 
elevated in most patients. Sixteen patients was treated with immunosuppressive drugs and the effect of immunosuppressive 
treatment was good. The clinical characteristics of RPF in Korean are similar with other studies except for higher proportion of male.
